UPDATE: Roth Capital Downgrades Ocugen, Inc. (OCGN) to Neutral Citing BLA for COVAXIN Timeline

Ocugen, Inc. (OCGN) PT Lowered to $4.50 at Chardan Capital Markets

Chardan Capital Markets analyst Keay Nakae lowered the price target on Ocugen, Inc. (NASDAQ: OCGN) to $4.50 (from $8.00) while maintaining a Neutral rating after the company announced that it will no longer seek to secure FDA Emergency Use Authorization (EUA) for Bharat Biotechs Covid-19 vaccine candidate, COVAXIN.

Pre-Open Stock Movers 06/10: (OXM) (ENZ) (RH) Higher; (OCGN) (MTLS) (CELH) Lower (more...)

Today's Pre-Open Movers:

Ocugen, Inc. (NASDAQ: OCGN) 29.7% LOWER; announced that upon recommendation from the U.S. Food and Drug Administration (FDA), it will pursue submission of a biologics license application (BLA) for its COVID-19 vaccine candidate, COVAXIN. The Company will no longer pursue an Emergency Use Authorization (EUA) for COVAXIN.

Materialise NV (NASDAQ: MTLS) 15.5% LOWER; announced today the pricing of its registered underwritten public offering of 4.0 million ADSs at a public offering price of... More

Ocugen (OCGN) Plunges 36% After Saying It Will No Longer Pursue Emergency Use Authorization for COVAXIN

Ocugen (NASDAQ: OCGN) Plunges 36% After Saying It Will No Longer Pursue an Emergency Use Authorization for COVAXIN

Ocugen (OCGN) To Pursue BLA, Not EAU for COVID-19 Vaccine Following FDA Recommendation

Ocugen, Inc. (NASDAQ: OCGN) (Company) announced that upon recommendation from the U.S. Food and Drug Administration (FDA), it will pursue submission of a biologics license application (BLA) for its COVID-19 vaccine candidate, COVAXIN. The Company will no longer pursue an Emergency Use Authorization (EUA) for COVAXIN.

... More